Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-225441 (Eszopiclone) in Generalized Anxiety Disorder
NCT00616655Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eszopiclone in generalized anxiety disorder (GAD), sponsored by Sumitomo Pharma America. Started Jan 2008; status: completed.
02
Drugs
eszopiclone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00616655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616655.